自体条件血清:一种新型疾病调节剂治疗膝骨关节炎的临床和功能结果。

IF 2.4 Journal of Drug Assessment Pub Date : 2020-03-25 eCollection Date: 2020-01-01 DOI:10.1080/21556660.2020.1734009
Matteo Vitali, Marco Ometti, Andreas Drossinos, Pierluigi Pironti, Luca Santoleri, Vincenzo Salini
{"title":"自体条件血清:一种新型疾病调节剂治疗膝骨关节炎的临床和功能结果。","authors":"Matteo Vitali,&nbsp;Marco Ometti,&nbsp;Andreas Drossinos,&nbsp;Pierluigi Pironti,&nbsp;Luca Santoleri,&nbsp;Vincenzo Salini","doi":"10.1080/21556660.2020.1734009","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> The purpose of this study was to investigate the potential ability of autologous conditioned serum (ACS) to decrease pain and improve joint functionality in patients affected by knee osteoarthritis (OA). <b>Methods:</b> Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. Each patient received 4 injections of ACS (Orthokine; orthogen, Dusseldorf, Germany) at the site of OA once per week for 4 weeks. Clinical and functional evaluation was performed using the VAS scale for pain, WOMAC scale and KSS functional and clinical scores before the first injection, at one week, at two weeks, at three weeks, at one month and at six months. Statistical analysis was done with the Wilcoxon Signed-Rank Test. <b>Results:</b> Our results show an improvement of all the evaluation scales at 6 months follow-up. Particularly, VAS scales among all patients decreased by 35.8% (<i>p</i> = .00148), KSS functional scores improved by 38.2% (<i>p</i> = .00148), KSS clinical scores improved by 28.9% (<i>p</i> = .00236) and WOMAC scores were reduced by 19.8% (<i>p</i> = .00188). Few adverse effects were observed in our sample. The most common complaint was pain and swelling in the subsequent days after performing the intra-articular injection. Only one patient reported rigidity following the injection of the ACS. <b>Conclusion:</b> Our results, in conjunction with preexisting studies in the medical literature regarding ACS, demonstrate the viability of this therapy for the treatment of knee OA, showing positive influence on pain and joint function without significant adverse effects.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":"9 1","pages":"43-51"},"PeriodicalIF":2.4000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21556660.2020.1734009","citationCount":"14","resultStr":"{\"title\":\"Autologous conditioned serum: clinical and functional results using a novel disease modifying agent for the management of knee osteoarthritis.\",\"authors\":\"Matteo Vitali,&nbsp;Marco Ometti,&nbsp;Andreas Drossinos,&nbsp;Pierluigi Pironti,&nbsp;Luca Santoleri,&nbsp;Vincenzo Salini\",\"doi\":\"10.1080/21556660.2020.1734009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> The purpose of this study was to investigate the potential ability of autologous conditioned serum (ACS) to decrease pain and improve joint functionality in patients affected by knee osteoarthritis (OA). <b>Methods:</b> Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. Each patient received 4 injections of ACS (Orthokine; orthogen, Dusseldorf, Germany) at the site of OA once per week for 4 weeks. Clinical and functional evaluation was performed using the VAS scale for pain, WOMAC scale and KSS functional and clinical scores before the first injection, at one week, at two weeks, at three weeks, at one month and at six months. Statistical analysis was done with the Wilcoxon Signed-Rank Test. <b>Results:</b> Our results show an improvement of all the evaluation scales at 6 months follow-up. Particularly, VAS scales among all patients decreased by 35.8% (<i>p</i> = .00148), KSS functional scores improved by 38.2% (<i>p</i> = .00148), KSS clinical scores improved by 28.9% (<i>p</i> = .00236) and WOMAC scores were reduced by 19.8% (<i>p</i> = .00188). Few adverse effects were observed in our sample. The most common complaint was pain and swelling in the subsequent days after performing the intra-articular injection. Only one patient reported rigidity following the injection of the ACS. <b>Conclusion:</b> Our results, in conjunction with preexisting studies in the medical literature regarding ACS, demonstrate the viability of this therapy for the treatment of knee OA, showing positive influence on pain and joint function without significant adverse effects.</p>\",\"PeriodicalId\":15631,\"journal\":{\"name\":\"Journal of Drug Assessment\",\"volume\":\"9 1\",\"pages\":\"43-51\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2020-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21556660.2020.1734009\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21556660.2020.1734009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21556660.2020.1734009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

摘要

目的:本研究的目的是探讨自体条件血清(ACS)减轻膝关节骨关节炎(OA)患者疼痛和改善关节功能的潜在能力。方法:选取15例有临床及影像学征象的膝关节OA患者作为研究对象。每位患者接受4次ACS (Orthokine;orthogen,杜塞尔多夫,德国)在OA现场每周一次,持续4周。采用首次注射前、第1周、第2周、第3周、第1个月和第6个月的疼痛VAS评分、WOMAC评分和KSS功能和临床评分进行临床和功能评价。统计学分析采用Wilcoxon sign - rank检验。结果:随访6个月,各项评价指标均有改善。其中,VAS评分下降35.8% (p = 0.00148), KSS功能评分提高38.2% (p = 0.00148), KSS临床评分提高28.9% (p = 0.00236), WOMAC评分降低19.8% (p = 0.00188)。在我们的样本中几乎没有观察到不良反应。最常见的主诉是关节内注射后数日的疼痛和肿胀。只有一名患者报告在注射ACS后出现僵硬。结论:我们的研究结果,结合已有的关于ACS的医学文献研究,证明了这种治疗膝关节OA的可行性,对疼痛和关节功能有积极的影响,没有明显的不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Autologous conditioned serum: clinical and functional results using a novel disease modifying agent for the management of knee osteoarthritis.

Objective: The purpose of this study was to investigate the potential ability of autologous conditioned serum (ACS) to decrease pain and improve joint functionality in patients affected by knee osteoarthritis (OA). Methods: Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. Each patient received 4 injections of ACS (Orthokine; orthogen, Dusseldorf, Germany) at the site of OA once per week for 4 weeks. Clinical and functional evaluation was performed using the VAS scale for pain, WOMAC scale and KSS functional and clinical scores before the first injection, at one week, at two weeks, at three weeks, at one month and at six months. Statistical analysis was done with the Wilcoxon Signed-Rank Test. Results: Our results show an improvement of all the evaluation scales at 6 months follow-up. Particularly, VAS scales among all patients decreased by 35.8% (p = .00148), KSS functional scores improved by 38.2% (p = .00148), KSS clinical scores improved by 28.9% (p = .00236) and WOMAC scores were reduced by 19.8% (p = .00188). Few adverse effects were observed in our sample. The most common complaint was pain and swelling in the subsequent days after performing the intra-articular injection. Only one patient reported rigidity following the injection of the ACS. Conclusion: Our results, in conjunction with preexisting studies in the medical literature regarding ACS, demonstrate the viability of this therapy for the treatment of knee OA, showing positive influence on pain and joint function without significant adverse effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Drug Assessment
Journal of Drug Assessment PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses. Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. Real-world experience of ocrelizumab in multiple sclerosis in an Arab population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1